The many pathways driving liver inflammation in MASH.
New regulatory approvals for liver disease require understanding multiple inflammatory pathways, guiding rational combination therapy design for MASH.
This Cell Metabolism review by Tilg, Loomba et al. provides an authoritative synthesis of MASH inflammatory pathway biology, timely given the first regulatory approvals for MASH therapies. Understanding pathway heterogeneity is directly relevant to combination treatment strategy design.
What the study was
- Study design
- Review
- Population
- MASH (metabolic dysfunction-associated steatohepatitis) patients
- Category
- Drug Development
- Maturity
- Validated
- Journal
- Cell Metabolism
Why it surfaced
High-profile review from leading MASH researchers in a top journal; useful pipeline context for cardiometabolic topic tracking but review design limits score.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.